• BioVersys will present exploratory Phase 2 BV100 efficacy and safety results at IDWeek in Washington, D.C., on October 23-24, 2026.
• The analysis covers 26 patients with ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii, using trial data published in 2024.
• The trial compared intravenous BV100 with polymyxin B against best available therapy.
• BV100 is recruiting patients in its Phase 3 registration trial, RIV-TARGET; a Phase 2b differentiation trial, RIV-CARE, is also underway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioversys AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2419920_en) on October 22, 2026, and is solely responsible for the information contained therein.